Related Experiment Video

Updated: Feb 2, 2026

In vitro Investigation of the MexAB Efflux Pump From Pseudomonas aeruginosa
13:40

In vitro Investigation of the MexAB Efflux Pump From Pseudomonas aeruginosa

Published on: February 17, 2014

12.2K

Interplay between MexAB-OprM and MexEF-OprN in clinical isolates of Pseudomonas aeruginosa

Gertrudis Horna1,2, María López3, Humberto Guerra2

  • 1Barcelona Institute for Global Health, ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.

Scientific Reports
|November 9, 2018
PubMed

Insights

The study reveals how the MexEF-OprN efflux pump system influences MexAB-OprM expression in Pseudomonas aeruginosa clinical isolates, impacting antibiotic resistance. Understanding this interplay is key to developing new strategies against multidrug-resistant bacteria.

Area of Science:

  • Microbiology
  • Molecular Biology
  • Antimicrobial Resistance Research

Background:

  • Pseudomonas aeruginosa utilizes efflux pumps like MexAB-OprM and MexEF-OprN to develop antibiotic resistance.
  • Previous research suggests the MexEF-OprN regulation system affects MexAB-OprM expression levels.

Purpose of the Study:

  • To investigate the interaction between MexAB-OprM and MexEF-OprN efflux pump systems in clinical Pseudomonas aeruginosa isolates.
  • To correlate genetic modifications in efflux pump regulators with antibiotic resistance phenotypes.

Main Methods:

  • Analysis of 90 clinical Pseudomonas aeruginosa isolates exhibiting efflux pump overexpression.
  • Identification of relevant modifications (RM) in genes including oprD, nalC, nalD, mexR, and MexS.
  • Statistical association analysis between genetic modifications and phenotypes like multidrug resistance (MDR) and carbapenem non-susceptibility.

Main Results:

  • 33% of isolates showed relevant modifications in oprD, linked to carbapenem resistance.
  • 33% displayed relevant modifications in regulators (nalC, nalD, mexR), associated with MDR, carbapenem resistance, OprD alterations, and biofilm production.
  • Modifications in MexS correlated with pigment production; however, MDR association with MexAB-OprM regulators was significant only when MexS was wild-type.

Conclusions:

  • The MexEF-OprN system modulates MexAB-OprM expression in a clinical context of Pseudomonas aeruginosa.
  • Genetic alterations in efflux pump regulators play a significant role in multidrug resistance and carbapenem resistance.
  • Targeting the interplay between these efflux pump systems could offer novel therapeutic strategies against antimicrobial resistance.

More Related Videos

Author Spotlight: Quantifying Siderophores and Pyochelin for Infection Control05:09

Author Spotlight: Quantifying Siderophores and Pyochelin for Infection Control

Published on: March 15, 2024

6.0K
Modeling Persistent Pseudomonas aeruginosa Infection in Wounded Zebrafish Larvae06:04

Modeling Persistent Pseudomonas aeruginosa Infection in Wounded Zebrafish Larvae

Published on: June 13, 2025

672

Related Concept Videos

Nursing Clinical Information System01:27

Nursing Clinical Information System

Nursing Clinical Information System (NCIS)
A Nursing Clinical Information System (NCIS) is a specialized type of healthcare information system tailored to meet the unique needs of nursing practice. It incorporates the principles of nursing informatics to streamline information management and improve the quality of care delivery.
Critical attributes of NCIS include:
1.3K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.5K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.0K
Changes in Skin Color: Clinical Perspectives01:14

Changes in Skin Color: Clinical Perspectives

The first thing a clinician sees is the skin, so the examination of the skin should be part of any thorough physical examination. Most skin disorders are relatively benign, but a few, including melanomas, can be fatal if untreated. A couple of the more noticeable disorders, albinism and vitiligo, affect the appearance of the skin and its accessory organs.
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
3.5K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.8K
Esophageal Perforation-II: Clinical Manifestations and Management01:28

Esophageal Perforation-II: Clinical Manifestations and Management

Esophageal perforations manifest in various clinical forms, influenced by factors such as the perforation's cause and location (cervical, intrathoracic, or intra-abdominal), the extent of contamination, and potential injury to adjacent mediastinal structures. The timing between the perforation occurrence and treatment initiation also affects the clinical presentation.
Clinical Manifestations:
727